News

join us for an informative, patient-centered webinar featuring cardiology and hematology experts, along with two patients sharing their lived experiences with…

AbstractThe therapeutic landscape for systemic immunoglobulin light chain (AL) amyloidosis has been revolutionized by daratumumab-based regimens, achieving 76% 5-…

At AstraZeneca, we turn ideas into life-changing medicines. Working here means being entrepreneurial, thinking big, and collaborating to make the impossible a…

Injectable therapy shows consistent benefits across high-risk ATTR-CM groupsNew analyses back the use of the approved therapy Amvuttra (vutrisiran) as an initial…

–    Of first 20 patients, all four MRD-negative patients have converted to complete response (CR)  ––   CR rate now 95% (19 of 20…

Multiparametric scores are effective for validating the AL score and increased wall thickness (IWT) scores in AL amyloidosis, according to a study being presented…

The overall aim of this observational study is to generate real-world evidence on the pre- and post-diagnosis disease journeys, including baseline characteristics,…

The injection therapy Wainua (eplontersen) “offers a vital ray of hope” for people living with hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN),…

This CardiaCast episode explores the latest advances in transthyretin amyloid cardiomyopathy (ATTR-CM) presented at ACC.26, with a focused review of newly released…

The investigational PET tracer iodine-124 (I-124) evuzamitide met its primary endpoints for the diagnosis of cardiac amyloidosis, including transthyretin-mediated…